{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:09:31Z","timestamp":1789664971010,"version":"4.0.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,17]]},"DOI":"10.7759\/cureus.116434","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:47:52Z","timestamp":1789663672000},"source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and Severity of Hepatic Steatosis and Fibrosis Across Glycemic Categories Among Patients Attending a Tertiary Care Hospital: A FibroScan-Based Cross-Sectional Study"],"prefix":"10.7759","author":[{"given":"Lisha","family":"Michel M","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Sayed Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Katalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshree","family":"Nambirajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arwa","family":"Leelawalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navana","family":"Hemanth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May Thazin","family":"Win","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinidas D","family":"S.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam M","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al.. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020, 73:202-9. 10.1016\/j.jhep.2020.03.039","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al.. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023, 79:1542-56. 10.1016\/j.jhep.2023.06.003","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis","volume":"41","author":"Mantovani A","year":"2018","unstructured":"Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care. 2018, 41:372-82. 10.2337\/dc17-1902","journal-title":"Diabetes Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, et al.. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019, 71:793-801. 10.1016\/j.jhep.2019.06.021","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam M","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020, 158:1999-2014.e1. 10.1053\/j.gastro.2019.11.312","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the Liver (EASL)\u2219 European Association for the Study of Diabetes (EASD)\u2219 European Association for the Study of Obesity (EASO)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL)\u2219 European Association for the Study of Diabetes (EASD)\u2219 European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024, 81:492-542. 10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi ZM","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023, 77:1335-47. 10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor RS","year":"2020","unstructured":"Taylor RS, Taylor RJ, Bayliss S, et al.. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020, 158:1611-25.e12. 10.1053\/j.gastro.2020.01.043","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al.. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023, 77:1797-835. 10.1097\/HEP.0000000000000323","journal-title":"Hepatology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/520798-prevalence-and-severity-of-hepatic-steatosis-and-fibrosis-across-glycemic-categories-among-patients-attending-a-tertiary-care-hospital-a-fibroscan-based-cross-sectional-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:47:53Z","timestamp":1789663673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/520798-prevalence-and-severity-of-hepatic-steatosis-and-fibrosis-across-glycemic-categories-among-patients-attending-a-tertiary-care-hospital-a-fibroscan-based-cross-sectional-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.116434","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}